JP2012520896A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520896A5
JP2012520896A5 JP2012500955A JP2012500955A JP2012520896A5 JP 2012520896 A5 JP2012520896 A5 JP 2012520896A5 JP 2012500955 A JP2012500955 A JP 2012500955A JP 2012500955 A JP2012500955 A JP 2012500955A JP 2012520896 A5 JP2012520896 A5 JP 2012520896A5
Authority
JP
Japan
Prior art keywords
agent
treatment
trifluoropentanamide
deutero
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012500955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027780 external-priority patent/WO2010107984A1/en
Publication of JP2012520896A publication Critical patent/JP2012520896A/ja
Publication of JP2012520896A5 publication Critical patent/JP2012520896A5/ja
Ceased legal-status Critical Current

Links

JP2012500955A 2009-03-19 2010-03-18 ベータアミロイドペプチド産生阻害剤としての重水素化された新規アルファ−(n−スルホンアミド)アセトアミド化合物 Ceased JP2012520896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16162909P 2009-03-19 2009-03-19
US61/161,629 2009-03-19
PCT/US2010/027780 WO2010107984A1 (en) 2009-03-19 2010-03-18 Novel alpha-(n-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production a novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production

Publications (2)

Publication Number Publication Date
JP2012520896A JP2012520896A (ja) 2012-09-10
JP2012520896A5 true JP2012520896A5 (https=) 2013-04-11

Family

ID=42312995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012500955A Ceased JP2012520896A (ja) 2009-03-19 2010-03-18 ベータアミロイドペプチド産生阻害剤としての重水素化された新規アルファ−(n−スルホンアミド)アセトアミド化合物

Country Status (7)

Country Link
US (1) US8044077B2 (https=)
EP (1) EP2408757B1 (https=)
JP (1) JP2012520896A (https=)
CN (1) CN102356071A (https=)
AR (1) AR075903A1 (https=)
TW (1) TW201038266A (https=)
WO (1) WO2010107984A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471099C (en) 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
JP2000515153A (ja) 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
AU766192B2 (en) 1999-01-27 2003-10-09 Wyeth Holdings Corporation Acetylenic sulfonamide thiol tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
CA2471099C (en) * 2001-12-20 2011-04-12 Bristol-Myers Squibb Company .alpha.-(n-sulphonamido)acetamide derivatives as .beta.-amyloid inhibitors
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
CA2544350A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1768960A1 (en) 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
AR059517A1 (es) 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
EP1984321A1 (en) 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
WO2009137657A1 (en) 2008-05-08 2009-11-12 Bristol-Myers Squibb Company 2-aryl glycinamide derivatives
CN102438622A (zh) 2009-03-19 2012-05-02 百时美施贵宝公司 作为β淀粉样肽产生抑制剂的新颖α-(N-磺酰氨基)乙酰胺化合物
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Similar Documents

Publication Publication Date Title
HRP20110219T1 (hr) Novi alfa-(n-sulfonamido)acetamidni spoj kao inhibitor proizvodnje beta amiloid peptida
JP2019059760A5 (https=)
JP2012532874A5 (https=)
JP2014521735A5 (https=)
IL229199A (en) N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
JP2012520896A5 (https=)
MX2011011489A (es) Derivados de isoxazol-piridina.
JP2018168191A5 (https=)
JP2017530983A5 (https=)
JO3695B1 (ar) تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
MX2011011477A (es) Derivados de isoxazol-piridazina.
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
JP2014511893A5 (https=)
RU2016141570A (ru) Комбинации ингибитора fgfr и ингибитора igf1r
JP2007514005A5 (https=)
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
JP2012512158A5 (https=)
JP2017522300A5 (https=)
ZA200802811B (en) Therapy for the treatment of disease
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
ZA200606804B (en) Pharmaceutical composition for treatment of immunological disorders
JP2015500223A5 (https=)
PL2111868T3 (pl) Zastosowanie ludzkiej albuminy do wytwarzania leku do leczenia pacjentów cierpiących na zaburzenia funkcji poznawczych